Investigational drug · Phase 2
GSK4527226
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alzheimer's Disease.
Phase 2Last checked: Nov 20, 2026Latest source record: Feb 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "GSK4527226"
First trial start
2025
Aug 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GSK4527226", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer's Disease
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "GSK4527226" as an intervention, largest first.
- Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's DiseasePivotal-lookingTerminated
GlaxoSmithKlineGSK (GSK)
NCT06079190 · 367 participants · Start Oct 20, 2023 · Primary completion May 14, 2026
Drug: GSK4527226 · For: Alzheimer's Disease
Sites: San Diego, California; Lake Mary, Florida; Lake Worth, Florida · 97 sites in all
GlaxoSmithKlineGSK (GSK)
NCT07105709 · 220 participants (planned) · Start Aug 14, 2025 · Primary completion Sep 15, 2028
Drug: GSK4527226 · For: Alzheimer's Disease
Sites: Maitland, Florida; Miami, Florida; Stuart, Florida · 33 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Development of AL101 (GSK4527226), a progranulin-elevating monoclonal antibody, as a potential treatment for Alzheimer's disease.
Budda B, Mitra A, Park L, et al. · Alzheimers Res Ther 2025
Also in development for Alzheimer's Disease
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- TrontinemabRO7126209, RG6102Phase 34 trials
Roche (Genentech) · Alzheimers Disease, Alzheimer's Disease
- [18F]-APN-1607Phase 32 trials
JYAMS PET Research & Development Limited · Alzheimer's Disease, Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
- RemternetugLY3372993Phase 31 trial
Eli Lilly · Alzheimer's Disease
- RO7568282Phase 22 trials
Roche (Genentech) · Parkinson's Disease, Alzheimer's Disease
- VHB937Phase 22 trials
Novartis · Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease
- ABBV-1758Phase 21 trial
AbbVie · Alzheimer's Disease
- E2814Phase 21 trial
Eisai · Alzheimer's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.